Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

BGB-16673-302

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (NCT06846671)

Currently recruiting

BGB-3111-308

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (NCT05100862)

Currently recruiting

BGB-3111-LTE1

An Open-label, Multi-centre, Long-term Extension Study of Zanubrutinib (BGB-3111) in patients with B-cell Malignancies (BGB-3111-LTE1) (NCT04170283)

No longer recruiting

BGB-A317-B167-101

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors (NCT05494762)

No longer recruiting

BGB-A317-LBL-007-201

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (NCT05609370)

Currently recruiting

BGB-C354-001

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (NCT06422520)

Currently recruiting

BHV3000-406

BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509400)

Currently recruiting

BI 1036-0130

Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) (NCT06241573)

No longer recruiting

Bi 1368-0140

A multi-centre, randomised, placebo-controlled, doubleblind, parallel-group trial to evaluate safety and efficacy of spesolimab [BI 655130] in adult patients with ulcerative pyoderma gangrenosum [PG] who require systemic therapy (NCT06624670)

Currently recruiting

BiVACOR

BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)

Currently recruiting

BJT-008-001

A Study to Evaluate Cavrotolimod in Subjects with Chronic Hepatitis B Virus [HBV] Infection (ACTRN12624000809538)

Currently recruiting

BJT-778-001

A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection (ACTRN12623000078651p - Cohort B and C. ACTRN12623000105640p - Cohort D and F. ACTRN12623000111673p - Cohort E)

Currently recruiting

BLENDER

Bend to Limit oxygEN in ECMO: a ranDomised controllEd Registry trial. (NCT03841084)

Recently completed/closed

BMS [IM011-132]

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) (NCT04857034)

Recently completed/closed

BO45287

A phase Ib open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Coming soon

BONANZA

Brain Oxygen Neuromonitoring in Australia and New Zealand Assessment - Global Trial (BONANZA-GT) (ACTRN12619001328167)

Currently recruiting

BONE ZONE

Bone Loss Prevention with Zoledronic Acid or Denosumab in Critically Ill Women – A Randomised Controlled Trial (NCT04608630)

Recently completed/closed

BOOST-IC

Bringing Optimised COVID-19 vaccine Schedules To Immunocompromised populations (BOOST IC) an adaptive randomised controlled clinical trial (NCT05556720)

Currently recruiting

BP41072

An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Obinutuzumab and in combination with Glofitamab following a pre-treatment of Obinutuzumab administered in participants with relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (NCT04077723)

Currently recruiting

BP44474

A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MICROSATELLITE INSTABILITY [MSI] AND/OR DEFICIENT MISMATCH REPAIR [DMMR] (NCT06004245)

Currently recruiting
4 5 6 7 8